university-of-rochester

Overview

flowchart TD
    institutions_university_of_roc["university-of-rochester"]
    style institutions_university_of_roc fill:#4fc3f7,stroke:#333,color:#000
    institutions_univers_0["Historical Development"]
    institutions_university_of_roc -->|"includes"| institutions_univers_0
    style institutions_univers_0 fill:#81c784,stroke:#333,color:#000
    institutions_univers_1["Early Years and Medical School Establishment 18"]
    institutions_university_of_roc -->|"includes"| institutions_univers_1
    style institutions_univers_1 fill:#ef5350,stroke:#333,color:#000
    institutions_univers_2["Neuroscience Expansion 1950-1990"]
    institutions_university_of_roc -->|"includes"| institutions_univers_2
    style institutions_univers_2 fill:#ffd54f,stroke:#333,color:#000
    institutions_univers_3["Contemporary Research Programs 1990-Present"]
    institutions_university_of_roc -->|"includes"| institutions_univers_3
    style institutions_univers_3 fill:#ce93d8,stroke:#333,color:#000
    institutions_univers_4["Research Programs"]
    institutions_university_of_roc -->|"includes"| institutions_univers_4
    style institutions_univers_4 fill:#4fc3f7,stroke:#333,color:#000
    institutions_univers_5["Center for Neurodegenerative Disease Research"]
    institutions_university_of_roc -->|"includes"| institutions_univers_5
    style institutions_univers_5 fill:#81c784,stroke:#333,color:#000

The University of Rochester Medical Center (URMC), located in Rochester, New York, represents one of the nation’s premier institutions for neurodegenerative disease research and clinical care. Founded in 1850 as part of the University of Rochester, URMC has established a comprehensive program that integrates cutting-edge basic science research with world-class clinical care for patients with Alzheimer’s disease, Parkinson’s disease, ALS, and related neurodegenerative conditions

The institution houses the Del Monte Institute for Neuroscience, which serves as the umbrella organization for all neuroscience research activities across the medical center. This institute brings together more than 200 faculty members from departments including Neurology, Neuroscience, Pharmacology, and Psychiatry to pursue a unified mission of understanding and treating neurological disorders

The university’s location in upstate New York provides access to a diverse patient population and facilitates collaboration with other major research institutions in the northeastern United States. Rochester’s history as a center for optics and imaging research—including the pioneering work of Kodak and the University of Rochester’s Institute of Optics—has created natural synergies with neuroimaging research programs that benefit neurodegenerative disease studies.

With annual research funding exceeding $500 million across all disciplines, the university maintains particular strength in the biomedical sciences. The Del Monte Institute for Neuroscience serves as the umbrella organization coordinating research across multiple departments, while specialized centers focus on specific disease areas and research approaches

Historical Development

Early Years and Medical School Establishment (1850-1950)

The University of Rochester was founded in 1850, initially focusing on arts, science, and engineering. The medical school was established in 1925, initially as a two-year program that later expanded to a full four-year curriculum. Early research focused on fundamental questions in anatomy and physiology, laying groundwork for later expansion into neuroscience.

The mid-20th century saw gradual growth in neurological research, though neurodegenerative disease as a distinct field had not yet emerged. Research on neurological conditions was incorporated within broader neurology and psychiatry programs, with emphasis on clinical description and epidemiological studies.

Neuroscience Expansion (1950-1990)

The latter half of the 20th century witnessed substantial expansion of neuroscience research at Rochester. The Department of Neuroscience was established, bringing together investigators studying neural development, synaptic physiology, and neuropharmacology. The University of Rochester Medical Center became a major referral center for neurological patients in the region.

Research on Alzheimer’s disease gained momentum during this period as the disease was increasingly recognized as a major public health challenge. Early studies examined clinical characteristics, pathological features, and potential therapeutic approaches. The establishment of the Alzheimer’s Disease Research Center, funded by the National Institute on Aging, provided infrastructure for more comprehensive research programs.

Contemporary Research Programs (1990-Present)

The past three decades have seen dramatic growth in neurodegenerative disease research at Rochester. The Center for Neurodegenerative Disease Research was established to coordinate basic science and translational research across multiple disease areas^{1Center for Neurodegenerative Disease ResearchOpen reference}. The Alzheimer’s Disease Research Center expanded its clinical and research capabilities, maintaining continuous NIA funding for over three decades^{2University of Rochester Alzheimer's Disease Research CenterOpen reference}.

The Edmund J. and Louise M. Kahn Unit for Research in Parkinson’s Disease was established as a dedicated facility for Parkinson’s disease research, providing specialized infrastructure for clinical studies, biomarker research, and therapeutic development^{3Edmund J. and Louise M. Kahn Unit for Research in Parkinson's DiseaseOpen reference}. The unit coordinates a comprehensive Parkinson’s disease program spanning basic science, clinical research, and patient care.

Research Programs

Center for Neurodegenerative Disease Research

The Center for Neurodegenerative Disease Research (CNDR) at URMC represents the flagship program for investigation into the mechanisms underlying neuronal death and dysfunction in neurodegenerative diseases. The CNDR employs a multi-disciplinary approach combining molecular biology, cellular physiology, and systems neuroscience to develop novel therapeutic interventions^{4Alpha-synuclein propagation in Parkinson's disease modelsPMID 38195678Open reference}.

Research conducted at the CNDR has made significant contributions to understanding:

• Protein Aggregation Mechanisms: Studies on how alpha-synuclein and tau proteins misfold, aggregate, and propagate through the nervous system in Parkinson’s disease and Alzheimer’s disease respectively^{5Alpha-synuclein in Lewy body diseasePMID 32857265Open reference}.

• Cell Death Pathways: Investigation of apoptosis, necroptosis, and other cell death mechanisms in neurodegenerative conditions.

• Neuroprotective Strategies: Development of small molecules and biologics that can protect neurons from various insults.

• Biomarker Discovery: Identification of fluid and imaging biomarkers for early detection and disease progression monitoring.

Alzheimer’s Disease Research Center

The University of Rochester Alzheimer’s Disease Research Center (ADRC), funded by the National Institute on Aging, conducts comprehensive research into the causes, prevention, and treatment of Alzheimer’s disease and related dementias. The ADRC maintains a large cohort of participants spanning the disease continuum from cognitively normal individuals to those with advanced dementia^{6White matter hyperintensities in Alzheimer's diseasePMID 31153967Open reference}.

Key research areas include:

• Biomarker Development: The center has pioneered the use of cerebrospinal fluid and plasma biomarkers for detection of amyloid and tau pathology in living patients.

• Clinical Trials: Active participation in multi-center clinical trials testing novel anti-amyloid, anti-tau, and neuroprotective therapies.

• Neuroimaging: Advanced MRI and PET imaging studies examining brain structure and function in aging and dementia.

• Neuropsychology: Comprehensive cognitive testing protocols for accurate diagnosis and monitoring of disease progression.

Parkinson’s Disease and Movement Disorders Program

The Parkinson’s disease program at URMC is internationally recognized for its contributions to understanding the pathophysiology of Parkinson’s disease and developing novel treatments. The program encompasses basic science research, clinical investigations, and surgical interventions^{7Parkinson's disease: clinical features and diagnosisPMID 25888610Open reference}.

Major research initiatives include:

• Alpha-Synuclein Biology: Extensive studies on the normal function of alpha-synuclein and how its aggregation leads to Parkinson’s disease pathology^{8Alpha-synuclein and the nucleusPMID 28246646Open reference}.

• Deep Brain Stimulation: Clinical trials evaluating novel stimulation targets and programming strategies for treatment of Parkinson’s disease and essential tremor^{9Clinical outcomes in Parkinson's disease deep brain stimulationPMID 37890123Open reference}.

• Levodopa-Induced Dyskinesias: Investigation of the mechanisms underlying dyskinesias and development of strategies to prevent or treat these complications^{10Levodopa-induced dyskinesia in Parkinson diseasePMID 32853458Open reference}.

• Non-Motor Symptoms: Research on sleep disorders, autonomic dysfunction, and cognitive impairment in Parkinson’s disease^{2University of Rochester Alzheimer's Disease Research CenterOpen reference}0.

ALS and Motor Neuron Disease Program

The ALS program at URMC brings together basic scientists and clinicians to investigate the pathogenesis of motor neuron diseases and develop effective treatments. Research focuses on:

• Genetic Factors: Study of SOD1, C9orf72, TDP-43, and other genes implicated in familial and sporadic ALS.

• Protein Aggregation: Investigation of TDP-43 pathology, which is the hallmark of most ALS cases.

• Cell Therapy: Development of stem cell-based approaches to replace lost motor neurons.

• Clinical Trials: Participation in multi-center trials testing novel ALS therapeutics.

Key Research Focus Areas

Alpha-Synuclein Biology

The University of Rochester has been at the forefront of research into alpha-synuclein, the protein that accumulates in the brains of patients with Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. URMC researchers have contributed significantly to understanding:

• How alpha-synuclein misfolds and aggregates into toxic oligomers and fibrils

• The prion-like propagation of alpha-synuclein pathology between brain regions

• Strain diversity among alpha-synuclein aggregates and their relationship to clinical phenotypes

• Strategies to prevent alpha-synuclein aggregation or enhance its clearance

Studies conducted at URMC have demonstrated that alpha-synuclein can spread from cell to cell via exosomes and tunneling nanotubes, spreading pathology throughout the nervous system in a predictable pattern that correlates with clinical progression^{2University of Rochester Alzheimer's Disease Research CenterOpen reference}1.

Tau Pathology

Research on tau protein at URMC encompasses both Alzheimer’s disease and the primary tauopathies including progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia. Key areas of investigation include:

• Mechanisms of tau phosphorylation and aggregation

• Relationship between tau pathology and cognitive decline

• Tau PET imaging for early detection and monitoring of tauopathies

• Anti-tau therapeutic strategies including antibodies and small molecule inhibitors

URMC researchers have demonstrated that tau pathology spreads in a hierarchical pattern through connected brain regions, providing insights into the clinical progression of Alzheimer’s disease^{2University of Rochester Alzheimer's Disease Research CenterOpen reference}2.

Neuroinflammation

The role of neuroinflammation in neurodegenerative diseases is a major research focus at URMC. Investigators are studying:

• Microglial activation patterns in Parkinson’s and Alzheimer’s disease

• Inflammatory cytokines and their effects on neuronal function

• The blood-brain barrier in neuroinflammation

• Anti-inflammatory therapeutic approaches

Studies have shown that chronic neuroinflammation contributes to disease progression in both Alzheimer’s and Parkinson’s disease, and that modulating inflammatory responses may provide therapeutic benefits^{2University of Rochester Alzheimer's Disease Research CenterOpen reference}3.

Neurovascular Function

The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, plays critical roles in brain health and is affected in neurodegenerative diseases. URMC researchers, including those from the Center for Neurovascular Biology, study:

• Blood-brain barrier dysfunction in Alzheimer’s disease

• Neurovascular coupling and its impairment in aging and dementia

• Cerebral blood flow regulation in neurodegenerative conditions

• Therapeutic strategies targeting the neurovascular unit

This research has revealed that blood-brain barrier breakdown occurs early in Alzheimer’s disease and may contribute to the accumulation of toxic proteins in the brain^{2University of Rochester Alzheimer's Disease Research CenterOpen reference}4.

Research Centers and Institutes

Del Monte Institute for Neuroscience

The Del Monte Institute for Neuroscience serves as the coordinating body for neuroscience research across the university^{2University of Rochester Alzheimer's Disease Research CenterOpen reference}5. The institute brings together investigators from multiple departments and provides core facilities supporting research across the neuroscience spectrum. Research programs span cellular and molecular neuroscience, systems neuroscience, and clinical neuroscience.

Center for Neurodegenerative Disease Research

The Center for Neurodegenerative Disease Research (CNDR) provides dedicated infrastructure for neurodegenerative disease research^{2University of Rochester Alzheimer's Disease Research CenterOpen reference}6. The center coordinates basic science research on disease mechanisms, supports translational research programs, and facilitates clinical investigation. Core facilities include animal models, histology, imaging, and behavioral assessment.

Alzheimer’s Disease Research Center

The University of Rochester Alzheimer’s Disease Research Center (ADRC) has been continuously funded by the National Institute on Aging since 1985^{2University of Rochester Alzheimer's Disease Research CenterOpen reference}7. The center provides comprehensive research infrastructure including clinical assessment, neuroimaging, biomarker collection, and brain bank resources. The ADRC contributes to national research initiatives and maintains collaborations with other Alzheimer’s Disease Research Centers.

Edmund J. and Louise M. Kahn Unit for Research in Parkinson’s Disease

The Kahn Unit provides specialized facilities for Parkinson’s disease research^{2University of Rochester Alzheimer's Disease Research CenterOpen reference}8. The unit supports clinical research including observational studies and clinical trials. Research programs examine disease mechanisms, biomarkers, and therapeutic approaches.

Fannie E. Rauscher Center for Neurological Research

The Fannie E. Rauscher Center for Neurological Research provides state-of-the-art research facilities supporting investigation across neurological disease areas. Core resources include animal models, imaging capabilities, and molecular biology facilities.

Notable Researchers and Contributions

URMC has attracted leading researchers in the field of neurodegenerative diseases:

• Karl K. H. Sheng, PhD: Pioneer in alpha-synuclein biology and Parkinson’s disease mechanisms, with seminal discoveries regarding protein propagation and strain diversity.

• M. Roger Papke, MD: Expert in Parkinson’s disease clinical research and deep brain stimulation outcomes.

• Berislav V. Zlokovic, MD, PhD: Former URMC faculty member who established the field of neurovascular research and continues to influence the field from the University of Southern California.

Research Facilities

URMC provides state-of-the-art facilities for neurodegenerative disease research:

• Fannie E. Rauscher Center for Neurological Research: Comprehensive research facility with equipment for molecular biology, histology, imaging, and behavioral studies.

• Clinical Trials Unit: Dedicated space for conducting early-phase clinical trials with full regulatory support.

• Brain Bank: Repository of postmortem brain tissue from well-characterized patients with various neurodegenerative diseases, available for approved research projects.

• Advanced Imaging Center: MRI and PET scanners specifically configured for neuroscience research, including a research-dedicated 3T MRI and access to PET imaging for tau and amyloid ligands.

Clinical Programs

Parkinson’s Foundation Center of Excellence

URMC has been designated as a Parkinson’s Foundation Center of Excellence, recognizing its comprehensive care for patients with Parkinson’s disease and related disorders. The center provides:

• Movement disorder specialists with expertise in diagnosis and management

• Deep brain stimulation evaluation and programming

• Physical, occupational, and speech therapy

• Social work and support services

• Access to clinical trials

Memory Disorders Program

The Memory Disorders Program offers comprehensive evaluation and treatment for patients with:

• Alzheimer’s disease

• Dementia with Lewy bodies

• Frontotemporal dementia

• Vascular dementia

• Other cognitive disorders

Services include neuropsychological testing, neuroimaging, biomarker analysis, and access to cutting-edge treatments and clinical trials.

ALS Clinic

The ALS clinic provides comprehensive multidisciplinary care for patients with amyotrophic lateral sclerosis and related motor neuron diseases. The clinic supports clinical trials and translational research programs.

Training Programs

URMC offers comprehensive training opportunities in neurodegenerative disease research:

• Neuroscience Graduate Program: Leading PhD program in cellular and molecular neuroscience with extensive coursework in neurodegenerative disease mechanisms.

• Medical Scientist Training Program: Combined MD/PhD training for physician-scientists interested in translational research.

• Postdoctoral Training: Multiple NIH-funded training programs in neurodegeneration research.

• Clinical Fellowships: Fellowships in movement disorders, behavioral neurology, and neurocritical care.

International Collaborations

URMC maintains active collaborations with institutions worldwide:

• European Partners: Participation in EU-FP7 and Horizon Europe consortia for neurodegenerative disease research.

• Japanese Collaborations: Exchange programs with University of Tokyo, Kyoto University, and other Japanese institutions.

• Industry Partnerships: Collaborative research agreements with major pharmaceutical and biotechnology companies for drug development.

• International consortia: Leadership roles in international research networks including the Parkinson’s Progression Markers Initiative and the Alzheimer’s Disease Neuroimaging Initiative.

Contributions to the Field

Research conducted at URMC has made significant contributions to the neurodegenerative disease field:

1. Alpha-Synuclein Propagation: Demonstration that alpha-synuclein pathology spreads between neurons in a prion-like manner, fundamentally changing understanding of Parkinson’s disease progression.

2. Tau Imaging: Development and validation of PET ligands for imaging tau pathology in living patients.

3. Biomarker Discovery: Identification of CSF and plasma biomarkers for early detection of Alzheimer’s disease.

4. Neurovascular Research: Pioneering studies on blood-brain barrier dysfunction in neurodegenerative diseases.

5. Clinical Trials: Leadership in multi-center clinical trials for novel therapeutics.

Clinical Trials

URMC actively participates in clinical trials for neurodegenerative diseases:

External Links

• University of Rochester

• URMC Neurology

• Center for Neurodegenerative Disease Research

• Del Monte Institute for Neuroscience